Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis

Li, Peiwei; Wu, Han; Zhang, Honghe; Shi, Yu; Xu, Jun; Yao, Ye; Xia, Dajing; Yang, Jun; Cai, Jianting; Wu, Yihua

doi:10.1136/gutjnl-2014-308260

Cited by 132 publications

(108 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lastly, other molecular events or epidemiological factors within the TIL/MMR subtypes may impact prognosis or chemosensitivity, which could contribute to the observed subtype-specific survival differences. Evidence supports potential roles for APC mutation,44 chromosome instability,45 tumour-associated stroma,24 body mass index,46 smoking47 and aspirin,48 among other factors.…”

Section: Discussionmentioning

confidence: 92%

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes

Williams

Mouradov

Jorissen

et al. 2018

Gut

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes

Williams

Mouradov

Jorissen

et al. 2018

Gut

View full text Add to dashboard Cite

show abstract

“…A new indication for aspirin as anticancer agent has been proposed in recent years [21][22][23][24][25]. This idea is mainly supported by data obtained from observational studies [26][27][28][29].…”

Section: Discussionmentioning

confidence: 94%

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Piazuelo

Esquivias

et al. 2016

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…[30-33] The degree of lymphocytic infiltrate in CRC tissue has been associated with MSI status and better patient survival. [34-38] However, there is a paucity of data on epidemiologic exposures (such as plasma 25(OH)D level) combined with tumour molecular features and immune response in the tumour microenvironment in population-based studies.…”

Section: Discussionmentioning

confidence: 99%

Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status

Song

Nishihara

Wang

et al. 2015

Gut

View full text Add to dashboard Cite

Objective Evidence suggests protective effects of vitamin D and anti-tumour immunity on colorectal cancer risk. Immune cells in tumour microenvironment can convert 25-hydroxyvitamin D [25(OH)D] to bioactive 1α,25-dihydroxyvitamin D3, which influences neoplastic and immune cells as an autocrine and paracrine factor. Thus, we hypothesised that the inverse association between vitamin D and colorectal cancer risk might be stronger for cancers with high-level immune response than those with low-level immune response. Design We designed a nested case-control study (318 rectal and colon carcinoma cases and 624 matched controls) within the Nurses’ Health Study and Health Professionals Follow-up Study, using molecular pathological epidemiology database. Multivariable conditional logistic regression was used to assess the association of plasma 25(OH)D with tumour subtypes according to the degree of lymphocytic reaction, tumour-infiltrating T-cells (CD3+, CD8+, CD45RO+ and FOXP3+ cells), microsatellite instability, or CpG island methylator phenotype. Results The association of plasma 25(OH)D with colorectal carcinoma differed by the degree of intratumoural periglandular reaction (Pheterogeneity=0.001); high 25(OH)D was associated with lower risk of tumour with high-level reaction [comparing the highest vs. lowest tertile: odds ratio, 0.10; 95% confidence interval, 0.03 to 0.35; Ptrend<0.001], but not risk of tumour with lower-level reaction (Ptrend>0.50). A statistically non-significant difference was observed for the associations of 25(OH)D with tumour subtypes according to CD3+ T-cell density (Pheterogeneity=0.03; adjusted statistical significance level of α=0.006). Conclusion High plasma 25(OH)D level is associated with lower risk of colorectal cancer with intense immune reaction, supporting a role of vitamin D in cancer immunoprevention through tumour-host interaction.

show abstract

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis

Abstract: These findings provide further indication that postdiagnosis aspirin therapy improved CRC overall survival, especially for patients with positive PTGS2 (COX-2) expression and mutated PIK3CA tumours.

Cited by 132 publications

References 35 publications

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status

Contact Info

Product

Resources

About